Bristol-Myers Squibb

Stock

ISIN: US1101221083

Ticker: BMY

US1101221083

BMY

Price

Discussion about BMY

Posts

Mikolaj

@Volcano

1Mon·

February 2025 Portfolio update

What a crazy rollercoaster this month it is.

$TXN (-7.04%) was my smallest position. I originally opened it to start and buy more later on so as to have a complete portfolio of 10 stocks what I was aiming for. The reason why I've sold it is I expect them to have financial issues that will lead to a dividend cut. I work in the electronics industry and TI has one of the nicest portfolios of electronic semiconductors, but financially I don't like how much debt they have at this moment and how small FCF they are generating. Furthermore, trump trade wars can also impact this company quite significantly so for me it is nota good fit at this moment.

$LMT (-3.69%) I believe is one of not many US stocks that will not be impacted that significantly in the upcoming years.

$VEUR (-5.74%) adding this ETF was a bit surprise, but since my priority at this moment are EU stocks it fits really nicely in my portfolio.

Transactions:

$ASML (-2.09%) - Bought x0.5 at €690.00

$LMT (-3.69%) - Bought x0.35 at $440.00

$VEUR (-5.74%) - Bought x3 at €42.70

$TXN (-7.04%) - Sold x0.35 at $184.14 (full position)

Dividends:

$ASML (-2.09%) x1 Dividends at €1.52

$MAIN (-6.56%) x10 Dividends at $0.25

$TXN (-7.04%) x0.35 Dividends at $1.36

$BMY (-3.51%) x3 Dividends at $0.62

Unrealized gain/loss: +1.47%

Realized gain/loss: -8.83% (-€5.977)

Dividendenopi👴

@Dividendenopi

2Mon·

Quo vadis healthcare sector?

My development in this area has been very mixed. After I sold in December $WBA (+0%) after a risky purchase - to lower the buy in - with +/- 0, my investment in $AFX (-6.58%) was abruptly terminated, leaving me with a hefty loss, and shortly afterwards I unfortunately also lost my shares in $UNH (-2%) but still with a profit of 8%. Today I decided to recoup my losses and sold my $BMY (-3.51%) sold. It was a nice trade, plus the €245 dividend plus the payment on February 3rd. The uncertainty in the sector has become too great for me and I want to watch from the sidelines what the new US government will do. Marty Makary as the planned head of the FDA will certainly not strike as brutally as some fear, but there could be changes and difficulties in the area of approval procedures. This would also affect Bristol, which should and must bring a few good products from its pipeline onto the market in the next few years. The acquisition of Karuma together with the approval of KarXT has provided a brief boost, but is not enough to compensate for the expiry of patent protection for Revlimid, Opdivo and especially Eliquis in the next few years. They account for over USD 12 billion of sales and patent protection expires in the EU in 2026 and in the US in 2028. This does not mean that Eliquis will no longer be sold, but a not insignificant proportion is likely to be lost to generics. In addition, CMS has already negotiated price reductions of 56% for 2026. Coupled with the political uncertainties, I have taken the money with me for the time being and will wait and see. I still have to deal with $NOVO B (-6.66%) ...., which is currently the biggest loss-maker in my portfolio with a drop of almost 17%.

Please let me know your assessment of the market in this sector.

06.01

Bristol-Myers Squibb

Sold x240 at €54.51

€13,082.40

23.68%

9 Comments

ThemenmitKopf@topicswithhead

2Mon

Well, cashing out now in the healthcare sector is probably the worst moment for the next few years. If you can, I would just wait until the situation eases. Innovation and cost reduction are still to come for the industry.

•

View all 3 further answers

Aktien Stammtisch

@Aktien_Stammtisch

4Mon·

Analyst updates, 04.12.

⬆️⬆️⬆️

- BARCLAYS raises the price target for SIEMENS from EUR 125 to EUR 130. Underweight. $SIE (-7.45%)

- BARCLAYS raises the target price for SIEMENS ENERGY from EUR 35 to EUR 36. Equal-Weight. $ENR (-9.65%)

- JEFFERIES raises the target price for ADYEN from EUR 1695 to EUR 1797. Buy. $ADYEN (-5.35%)

- JPMORGAN raises the target price for SALESFORCE from USD 340 to USD 380. Overweight. $CRM (-5.08%)

- HSBC raises the target price for ZALANDO from EUR 37 to EUR 40. Buy. $ZAL (-7.88%)

- JPMORGAN raises the target price for RHEINMETALL from EUR 680 to EUR 800. Overweight. $RHM (-10.98%)

- DEUTSCHE BANK RESEARCH raises the target price for COCA-COLA HBC from GBP 31.50 to GBP 32. Buy. $CCH (-3.29%)

- BARCLAYS raises the target price for KNORR-BREMSE from EUR 55 to EUR 60. Underweight. $KBX (-8.01%)

- BARCLAYS raises the price target for ABB from CHF 40 to CHF 42. Underweight. $ABBNY (-5.19%)

- BARCLAYS raises the price target for ALSTOM from EUR 8 to EUR 9. Underweight. $ALO (-7.91%)

- HSBC upgrades MERCK & CO to Buy. Target price USD 130. $MRK (-4.87%)

- JPMORGAN raises the target price for DSV from DKK 1685 to DKK 1800. Overweight. $DSV (-7.13%)

- JPMORGAN raises the target price for LUFTHANSA from EUR 4.80 to EUR 5.50. Underweig$LHA (-6.02%)

- UBS raises the target price for AROUNDTOWN from EUR 2 to EUR 3.30. Neutral. $AT1 (-8.29%)

⬇️⬇️⬇️

- JPMORGAN lowers the target price for DHL GROUP from EUR 47 to EUR 42.50. Overweight. $DHL (-6.85%)

- WARBURG RESEARCH lowers the target price for UNITED INTERNET from EUR 38.50 to EUR 37.30. Buy. $UTDI (-7.38%)

- WARBURG RESEARCH lowers the target price for 1&1 from EUR 23.50 to EUR 19.10. Buy. $1U1 (-9.33%)

- WARBURG RESEARCH lowers the target price for KWS SAAT from EUR 89 to EUR 88. Buy. $KWS (-2.47%)

- DEUTSCHE BANK RESEARCH downgrades HEINEKEN from Buy to Hold and lowers target price from EUR 95 to EUR 76. $HEIA (-1.87%)

- EXANE BNP lowers the price target for SCHOTT PHARMA from EUR 36 to EUR 28. Neutral. $1SXP (-6.44%)

- BARCLAYS downgrades SIGNIFY to Underweight. Target price EUR 18. $LIGHT (-5.81%)

- CFRA downgrades BRISTOL-MYERS SQUIBB to Hold. Target price USD 60. $BMY (-3.51%)

- MORGAN STANLEY downgrades MOLLER-MAERSK to Underweight. Target price DKK 12200. $AMKBY (-10.8%)

- BARCLAYS downgrades ANDRITZ to Underweight. Target price EUR 40. $ANDR (-5.65%)

- JPMORGAN lowers the price target for HAPAG-LLOYD from EUR 85 to EUR 80. Underweight. $HLAG (-7.03%)

Aktien Stammtisch

@Aktien_Stammtisch

4Mon·

$ABBV (-7.06%)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway

$BMY (-3.51%) Bristol-Myers Squibb seems to benefits from this +13%

11 Comments

Sebastian B.@Baisse-Jumper

4Mon

Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒

•

Stefan

@Slucks87

4Mon·

$BMY (-3.51%) What's going on here?

1 Comment

Vítor R.@Victori98pt

4Mon

https://getqu.in/Tfvtxo/ 👀

••

Marc

@Massa93

5Mon·

I would like to slim down my portfolio and would like some tips from you on which stocks you would get rid of. As I haven't decided on a strategy, my portfolio consists of the three pillars of growth, dividends and ETFs.

So far I would get rid of the smallest positions I have as well as $BMY (-3.51%)
$BATS (-4.36%) and $MMM (-8.14%)

78Positions

€281,106.13

52.10%

5 Comments

Marcin Kummer@MartyMcFly

5Mon

Diworsification - what's not a strategy or a "3 pillar strategy"? You can have the fastest boat, car, airplane, bike, scooter, but if you don't have a destination, you'll never get there...

•

Show answer

Enrique

@Dividenden_Monteur

5Mon·

$BMY (-3.51%) closed before the weekend and took a small profit.

$CVS (-4.46%) is dragging down the healthcare sector and the share is moving sideways in the hourly chart.

Better safe than sorry.

18.10

CAL

Call @50.95USD Bristol Myers Open-End

Sold x1231 at €0.227

€279.44

9.66%

4 Comments

Kate💎 🙌.@Iwanowitsch

5Mon

When will there be coaching? :)

•

View all 3 further answers

Enrique

@Dividenden_Monteur

6Mon·

With $BMY (-3.51%) my losses from the $MA (-7.72%) trade.

Overall a positive week with realized +372€ from KO bills

27.09

CAL

Call @48USD Bristol Myers Open-End

Sold x2185 at €0.38

€830.30

100.00%

2 Comments

Andreas W.@Wottsak9

6Mon

Why has BMY risen so much today?

••

Show answer

Kai

@fcsp

6Mon·

Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy | Fierce Pharma

The share price is finally making another leap. It can continue like this.

$BMY (-3.51%)

www.fiercepharma.comJust a moment...

Kate💎 🙌.

@Iwanowitsch

6Mon·

I think I will sell the following titles:

These stocks are very heavily represented in the MSCI World. This reduces cluster risk and frees up capital for speculative growth stocks.

-----------------------------------------------------

The REITs remain for the time being as they have positive momentum and will benefit strongly from future interest rate cuts.

------------------------------------------------------

$MRK (-4.87%)

$PFIZER

$JNJ (-3.01%)

Flying out as I don't understand the industry well enough.

$HIMS (-7.52%) remains, on the other hand.

------------------------------------------------------

Defensive stocks are out, as no excess return is to be expected here.

--------------------------------------------------------

$AMD (-8.01%) and $INTC (-10.9%) These are my turnaround candidates, as soon as this is completed, they are out

--------------------------------------------------------

The following titles are also on the hit list:

-----------------------------------------------------------

What do the more experienced among you say? Are there any titles on my list that are worth keeping? Do you see any gross misjudgments? Do you have any suggestions for improvement?

Thanks in advance.

Kate💎 🙌.

@Iwanowitsch

6Mon·

Hey everyone,

I'm currently facing the challenge of reducing my portfolio from 77 to a maximum of 30 shares in order to get a better overview and focus my strategy. But I'm not sure how best to proceed.

Should I:

Sell the stocks that have done badly as they are obviously not performing well?
Or should I rather sell the ones that have performed best in order to take profits before things go downhill?
Or simply sell the 40 smallest positions? But there are also many interesting stocks in there that might be worth expanding.
Or simply sell everything that is heavily weighted in the MSCI World and thus reduce the cluster risk?

Perhaps there is a better approach? What do you look for when reducing your positions? Diversification, dividend yield, or simply the size of the individual positions in relation to the overall portfolio? I look forward to your opinions and tips!

Thanks in advance!

77Positions

15.75%

23 Comments

Soprano@Soprano

6Mon

That doesn't make sense, no. If you are already investing in individual stocks, why are you throwing out the best ones to go into "speculative growth stocks"?
The same applies to the healthcare sector. If you don't understand the established players, in what constellation do you understand those that are difficult to assess anyway? Defensive stocks are out ... because they are defensive? And AMD is not a "turnaround candidate" - you simply bought far too expensively.

All in all, it gives the impression that you don't really understand individual stocks, i.e. which stocks to buy why and how to value the companies in the first place. I also don't know if you're interested in learning, otherwise you should probably just stick to ETFs (I'm very reluctant to recommend that).

But what it shouldn't be, at least, is that you look at individual stocks as something where you pick the ones that tell a nice story in the hope that you're going to beat the market big time.

•

Trending Securities

Top creators this week

LSX Data · Fundamentals & EOD data from FactSet